TP53 and diffuse large B-cell lymphoma: Recently, we reported that A-DLBCL had a high frequency of TP53 mutations and concurrent MYC and BCL2 and/or BCL6 genetic abnormalities, indicating that the clinicopathologic features and aggressive behavior of A-DLBCL are distinct from the common DLBCL [6].